Results 201 to 210 of about 128,993 (222)
Some of the next articles are maybe not open access.

The pharmaceutical industry tussles over biosimilars: federal and state decisions will have a big impact on pharmacists.

P & T : a peer-reviewed journal for formulary management, 2014
Unlike a generic drug, a "generic" biologic won't be identical to the branded product. Manufacturers are divided over whether pharmacists should have to tell doctors when they prescribe one of the "biosimilars" that will soon appear on the market.
openaire   +1 more source

Biosimilar Monoclonal Antibodies in China: A Patent Review

Bioengineered, 2022
Ji-Fu Wei, Nan Wu
exaly  

Outlook For Biosimilar Molecules Entering Croatian Pharmaceutical Market In The Period From 2016 To 2020

Clinical Therapeutics, 2016
R, Likic   +7 more
openaire   +2 more sources

Clinical Safety of Biosimilar Recombinant Human Erythropoietins

Expert Opinion on Drug Safety, 2012
Karen M MacDonald, Ivo Abraham
exaly  

Clinical Safety of Biosimilar Recombinant Human Granulocyte Colony-Stimulating Factors

Expert Opinion on Drug Safety, 2013
Karen M MacDonald, Ivo Abraham
exaly  

Home - About - Disclaimer - Privacy